AstraZeneca Announces Partnership With Illumina To Develop Gene Sequencing Panel

Thu, 08/21/2014 - 3:23pm

AstraZeneca announced that it has entered into a collaboration with gene sequencing company Illumina, Inc. to develop its next generation sequencing (NGS) platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio. In the first instance, AstraZeneca intends to apply Illumina’s cutting-edge technology to a novel companion diagnostic test in pivotal studies for one of its investigational oncology compounds. This is expected to be one of the first NGS-based companion diagnostic tests for a novel drug in the world, and its application could speed the clinical trial process.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.